Page 2 - Slide 1

Amgen Bone Health Mentoring Program

Monday, October 15, at 11:30am – 2:30pm ◼ Ruth Chris, Minneapolis, MN

1025 Inhibition of Sclerostin With AMG 785 in

Postmenopausal Women With Low Bone Mineral

Density: Phase 2 Trial Results.

McClung M, Grauer A, Boonen S et al.

Session: Concurrent Oral Session 05: John H. Carsten's
Memorial Session for Osteoporosis Treatment◼
Saturday , October 13, 09:30 AM - 09:45 AM◼

Auditorium-Main/Minneapolis Convention Center

Abstract Information Additional Notes from
Poster/Presentation*
Backgro ▪ Sclerostin-neutralizing antibodies are
und associated with increases in bone Strengths, Weaknesses, Key
mass and strength Points
Methods
▪ This international phase-2 study
describes the efficacy and safety of
the human sclerostin antibody AMG
785/CDP7851 in 419 PM women with
a low BMD

▪ Eligibility criteria: PM women aged
55 to 85 years with a lumbar spine,
total hip, or femoral neck T-score ≤–
2.0 and ≥–3.5

▪ PM women were randomized to
receive one of 5 regimens of
subcutaneous AMG 785 (70 mg QM,
140 mg QM, 210 mg QM, 140 mg
Q3M, 210 mg Q3M) or placebo and
open-label ALN or TPTD

▪ Primary end point: % change from
baseline in lumbar spine BMD at
month 12

* Assignment notes will be collected at the Amgen Mentoring Program Debrief Meeting. Hardcopy or Electronic versions are acceptable